Literature DB >> 23218434

Cost of rheumatic disorders in the Netherlands.

M Elske van den Akker-van Marle1, Astrid M J Chorus, Thea P M Vliet Vlieland, Wilbert B van den Hout.   

Abstract

Rheumatic disorders concern a broad spectrum of painful disorders affecting the musculoskeletal system, and are responsible for a considerable amount of disease burden and also a substantial economic burden. This economic burden consists of direct and indirect costs, but also the so-called intangible costs. In this study, we estimated the societal cost of rheumatic disorders in the Netherlands, including intangible costs. Data from the National Monitor on Musculoskeletal System 2010 were used to assess resource used, multiplied with standard prices for the Netherlands to obtain total costs for the 1.8 million people suffering from rheumatic disorders. These estimates were supplemented with data from secondary sources. Total societal costs of rheumatic disorders in the Netherlands amount to €4.7 million a year, that is, €2665 per person with rheumatic disorders. Rheumatic disorders have considerable costs, which justify more attention in discussing investments in facing the challenges in our ageing Western societies.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23218434     DOI: 10.1016/j.berh.2012.08.005

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  6 in total

1.  Socio-economic gradients in the presence of musculoskeletal and other chronic diseases: results from a cross-sectional study in the Netherlands.

Authors:  P Putrik; S Ramiro; A M Chorus; A P Keszei; A Boonen
Journal:  Clin Rheumatol       Date:  2018-06-12       Impact factor: 2.980

2.  More economic evaluations are needed in calculating the burden of wound care.

Authors:  Yi-Ping Song; Hong-Lin Chen
Journal:  Int Wound J       Date:  2020-04-29       Impact factor: 3.315

3.  Quality of Care in Rheumatoid Disease from the Clinician Perspective: A Modified Delphi Panel Approach.

Authors:  Finbar O'Shea; Peter C Taylor; Gavin Dickie; Andrew Yaworsky; Benjamin Banderas; Sumesh Kachroo
Journal:  Rheumatol Ther       Date:  2018-04-03

4.  Work outcome in persons with musculoskeletal diseases: comparison with other chronic diseases & the role of musculoskeletal diseases in multimorbidity.

Authors:  Antje van der Zee-Neuen; Polina Putrik; Sofia Ramiro; Andras Keszei; Rob de Bie; Astrid Chorus; Annelies Boonen
Journal:  BMC Musculoskelet Disord       Date:  2017-01-10       Impact factor: 2.362

5.  Socioeconomic inequities in perceived health among patients with musculoskeletal disorders compared with other chronic disorders: results from a cross-sectional Dutch study.

Authors:  P Putrik; S Ramiro; A M Chorus; A P Keszei; A Boonen
Journal:  RMD Open       Date:  2015-05-21

6.  Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial.

Authors:  Marieke M Ter Wee; Veerle Mh Coupé; Debby den Uyl; Birgit S Blomjous; Esmee Kooijmans; Pit Jsm Kerstens; Mike T Nurmohamed; Dirkjan van Schaardenburg; Alexandre E Voskuyl; Maarten Boers; Willem F Lems
Journal:  RMD Open       Date:  2017-10-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.